on OXURION (EBR:OXUR)
Oxurion Clears Regulatory Hurdle in Axiodis Acquisition
Oxurion NV, a biopharmaceutical company headquartered in Leuven, Belgium, has announced the fulfilment of the second condition precedent for acquiring 72% of Axiodis CRO's share capital. The acquisition is executed through Oxurion's French subsidiary.
The French Ministry for the Economy, Finance and Industrial and Digital Sovereignty confirmed that the transaction is not subject to foreign investment control as per French regulations. This clears a significant regulatory step related to the Foreign Direct Investment procedure.
Oxurion is in the final stages of arranging financing for this acquisition, with plans to complete the transaction within 30 days.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news